

SKYEPHARMA PLC
Form 6-K
April 17, 2007

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of April, 2007

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

**SkyePharma PLC ("the Company")
Notification of Major Interest in Shares**

Edgar Filing: SKYEPHARMA PLC - Form 6-K

In accordance with paragraph 5.1.2 of the Disclosure and Transparency Rules, the Company has received a notification dated 13 April 2007 from Aviva plc and its subsidiaries ("Aviva") stating that as at 11 April 2007, it held a notifiable interest of 83,999,653 shares in SkyePharma PLC, which represents 10.31% of the voting rights in the Company. 9.62% are held directly and 0.69% are held indirectly.

Direct holdings:	BNY Norwich Union Nominees Limited	19,270,661 shares
	Chase GA Group Nominees Limited	41,674,191 shares
	Chase Nominees Limited	1,381,373 shares
	CUIM Nominee Limited	15,859,401 shares
	Vidacos Nominees Limited	<u>222,791 shares</u>
		78,408,417 shares (9.62%)
Indirect holdings:	Chase Nominees Limited	1,361,734 shares
	CUIM Nominee Limited	859,130 shares
	Vidacos Nominees Limited	<u>3,370,372 shares</u>
		5,591,236 Shares (0.69%)

Prior to the triggering transaction, Aviva held 43,183,326 Ordinary Shares and notifies the Company that the percentage thresholds that have been crossed are 6% to 10% (inclusive) at the combined interest level.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ John Murphy

Name: John Murphy
Title: Company Secretary

Date: April 17, 2007